{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000446","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.890114+00:00","generated_at":"2026-06-04T09:42:49.206831+00:00","sec_items":["1.0"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity","bullets":["Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.","Quarterly minimum fees reduced: $84,000 for May & Aug 2024, then $174,000 through Aug 2025.","Previous schedule had fees up to $332,500/quarter from Nov 2025; now capped at $174,000.","Amendment effective March 15, 2024; signed by all parties on March 21, 2024.","Parentco assumed obligations after acquiring Premier in November 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000446","json":"https://secwatch.observer/filing/0001640334-24-000446.json","markdown":"https://secwatch.observer/filing/0001640334-24-000446.md","text":"https://secwatch.observer/filing/0001640334-24-000446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/0001640334-24-000446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:42:49.206831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}